Please provide your email address to receive an email when new articles are posted on . Overall, 56% of participants had a lupus nephritis class change on repeat biopsy. Of patients with initial ...

In a cross-sectional study, insulin growth factor binding protein 2 (IFGBP-2) showed promise as a prognosis biomarker for renal disease in pediatric lupus nephritis (LN). Serum insulin growth factor ...

Belimumab showed efficacy in a subgroup of patients with lupus nephritis treated with MMF as standard of care background therapy. Belimumab reduces proteinuria in patients with class 3 or 4 lupus ...

In reflecting on the American College of Rheumatology conference, Dr Maureen McMahon describes the impact of new guidelines on early diagnosis in systemic lupus erythematosus (SLE) and lupus nephritis ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Glomerular disease in LN is a dynamic process with the potential for glomerular lesions to transform from one pattern to another. 1-4 Adjacent glomeruli may show different degrees of involvement. The ...

Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, is reporting the first use of the powerful imaging mass cytometry (IMC) to examine the kidneys of patients ...

Please provide your email address to receive an email when new articles are posted on . Lupus nephritis is a common complication of systemic lupus erythematosus. New therapies are now available with ...

Patients who received obinutuzumab were less likely to experience a renal-related event or death, compared with those who received placebo. The Food and Drug Administration (FDA) has approved Gazyva ® ...

Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis ...

This transcript has been edited for clarity. Matthew A. Sparks, MD: I'm Dr Matthew Sparks, and welcome to Medscape's InDiscussion podcast series on chronic kidney disease. Today we'll be discussing ...